Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ELVN
ELVN | US
44.25
USD0.36
0.82%
ELVN | US
Loading StockChartView...
About ELVN
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
44.25
Open
44.00
High
44.53
Low
43.26
Enliven Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001 which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002 a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder Colorado.
View LessELVN | US
Risk
84.8
Sharpe
1.71
Luna's Score
52/100
Recommendation
Hold
Luna says (ELVN | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
48.5%1 month
84.8%3 months
67.6%6 months
99.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.49
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-6.28
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-95.95M
MarketCap
2.09B
MarketCap(USD)
2.09B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-28.37
Short ratio
26.76
Short perc.
31.97
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
5.97
Range1M
14.78
Range3M
23.64
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.43
Price X volume
29.52M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -6.28 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.49 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 67.59 | 72.80 | Par |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 2.09B | 3.66B | Emerging |
